Building 560 replace reheat water heat exchangers and condensate pumps (WO 125265)
Ended Awarded Last action
- Contract number
- 75N91019F00129
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,955,335
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $2,955,335.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,955,335 |
About this award
The National Cancer Institute awarded a $2.96M delivery order contract to Leidos Biomedical Research Inc. for the replacement of reheat water heat exchangers and condensate pumps in Building 560 at its Frederick, Maryland facility. Awarded on May 15, 2019, with an ultimate completion date of April 6, 2021, this cost-plus-fixed-fee delivery order required no set-aside designation. The work order (WO 125265) supports critical facilities infrastructure improvements at the Frederick National Laboratory for Cancer Research, where Leidos operates as a Federally Funded Research and Development Center (FFRDC) contractor providing comprehensive biomedical research and facilities support services to the National Institutes of Health enterprise.
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., has established itself as a primary facilities and research support provider to the National Cancer Institute and broader NIH mission through multiple cost-plus-fixed-fee delivery orders. The contractor's FFRDC role encompasses diverse capabilities spanning cancer research, clinical trials, advanced laboratory services, and mission-critical facility management. This facilities modernization project reflects the ongoing investment in infrastructure that enables the Frederick National Laboratory to maintain operational excellence and support the full spectrum of biomedical research activities conducted under the National Cancer Institute's cancer research and development mandate.
Quick answers
Who was awarded contract 75N91019F00129?
75N91019F00129 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on May 15, 2019.
How much is contract 75N91019F00129 worth?
The government has obligated $2,955,335 on 75N91019F00129.
Is contract 75N91019F00129 an order under another contract?
Yes. 75N91019F00129 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91019F00129 competed?
The extent of competition for 75N91019F00129 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award